[Comparative study of the reactivity, safety and immunogenicity of "Havrix" inactivated hepatitis A vaccine].
This paper sums up the results of controlled field clinical trials of adult and childhood variants of Harvix, inactivated vaccine from hepatitis A. The vaccine is weakly reactogenic and safe. After a single injection of Harvix-1440 vaccine to adults the percentage of seroconversions in previously seronegative individuals was 80.6%, with the mean geometrical antibody titer 119 mIU/ml. In children aged 3-10 years the percentage of seroconversions after a single injection of Harvix-720 vaccine was 100%, the mean geometrical of antibody titer being 427 mIU/ml. Results of laboratory control and field clinical trials recommend both variants of Harvix vaccine for prevention of hepatitis A in the Russian Federation.
Noskova
A V
AV
Gorbunov
M A
MA
Pavlova
L I
LI
El'shina
G A
GA
Sharipova
I S
IS
Karpovich
L G
LG
Kalashnikova
T I
TI
Bektimirov
T A
TA
Rikhmer
V V
VV
El'nikov
V S
VS
D002648:Child; D002675:Child, Preschool; D018849:Controlled Clinical Trials as Topic; D006506:Hepatitis A / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000009:adverse effects* / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D010919:Placebos; D015164:Vaccines, Inactivated / Q000009:adverse effects* / Q000276:immunology*
D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D010919:Placebos; D015164:Vaccines, Inactivated
Sravnitel;noe izuchenie reaktogennosti, bezopasnosti i immunoennosti inaktivirovannykh vaktsin protiv gepatita A "Havrix".